Literature DB >> 17324123

Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB.

Faiyaz Ahmad1, Rebecka Lindh, Yan Tang, Marie Weston, Eva Degerman, Vincent C Manganiello.   

Abstract

Fractionation of 3T3-L1 adipocyte membranes revealed that PDE3B (phosphodiesterase 3B) was associated with PM (plasma membrane) and ER (endoplasmic reticulum)/Golgi fractions, that insulin-induced phosphorylation/activation of PDE3B was greater in internal membranes than PM fractions, and that there was no significant translocation of PDE3B between membrane fractions. Insulin also induced formation of large macromolecular complexes, separated during gel filtration (Superose 6 columns) of solubilized membranes, which apparently contain phosphorylated/activated PDE3B and signalling molecules potentially involved in its activation by insulin, e.g. IRS-1 (insulin receptor substrate-1), IRS-2, PI3K p85 [p85-subunit of PI3K (phosphoinositide 3-kinase)], PKB (protein kinase B), HSP-90 (heat-shock protein 90) and 14-3-3. Expression of full-length recombinant FLAG-tagged murine (M) PDE3B and M3BDelta604 (MPDE3B lacking N-terminal 604 amino acids) indicated that the N-terminal region of MPDE3B was necessary for insulin-induced activation and recruitment of PDE3B. siRNA (small interfering RNA) knock-down of PDE3B indicated that PDE3B was not required for formation of insulin-induced complexes. Wortmannin inhibited insulin-induced assembly of macromolecular complexes, as well as phosphorylation/activation of PKB and PDE3B, and their co-immunoprecipitation. Another PI3K inhibitor, LY294002, and the tyrosine kinase inhibitor, Genistein, also inhibited insulin-induced activation of PDE3B and its co-immunoprecipitation with PKB. Confocal microscopy indicated co-localization of PDE3B and PKB. Recombinant MPDE3B co-immunoprecipitated, and co-eluted during Superose 12 chromatography, to a greater extent with recombinant pPKB (phosphorylated/activated PKB) than dephospho-PKB or p-DeltaPKB [pPKB lacking its PH domain (pleckstrin homology domain)]. Truncated recombinant MPDE3B proteins and pPKB did not efficiently co-immunoprecipitate, suggesting that structural determinants for their interaction reside in, or are regulated by, the N-terminal portion of MPDE3B. Recruitment of PDE3B in macromolecular complexes may be critical for regulation of specific cAMP pools and signalling pathways by insulin, e.g. lipolysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324123      PMCID: PMC1868803          DOI: 10.1042/BJ20060960

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms.

Authors:  Y Kenan; T Murata; Y Shakur; E Degerman; V C Manganiello
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

Review 2.  Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family.

Authors:  Y Shakur; L S Holst; T R Landstrom; M Movsesian; E Degerman; V Manganiello
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

3.  Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes.

Authors:  Svante Resjö; Olga Göransson; Linda Härndahl; Stanislaw Zolnierowicz; Vincent Manganiello; Eva Degerman
Journal:  Cell Signal       Date:  2002-03       Impact factor: 4.315

4.  Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.

Authors:  T Sudo; K Tachibana; K Toga; S Tochizawa; Y Inoue; Y Kimura; H Hidaka
Journal:  Biochem Pharmacol       Date:  2000-02-15       Impact factor: 5.858

5.  Cyclic nucleotide phosphodiesterase 3B is a downstream target of protein kinase B and may be involved in regulation of effects of protein kinase B on thymidine incorporation in FDCP2 cells.

Authors:  F Ahmad; L N Cong; L Stenson Holst; L M Wang; T Rahn Landstrom; J H Pierce; M J Quon; E Degerman; V C Manganiello
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

6.  Insulin signalling and the regulation of glucose and lipid metabolism.

Authors:  A R Saltiel; C R Kahn
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

7.  Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum.

Authors:  Y Shakur; K Takeda; Y Kenan; Z X Yu; G Rena; D Brandt; M D Houslay; E Degerman; V J Ferrans; V C Manganiello
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

Review 8.  Cyclic nucleotide phosphodiesterases: relating structure and function.

Authors:  S H Francis; I V Turko; J D Corbin
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

9.  14-3-3 facilitates insulin-stimulated intracellular trafficking of insulin receptor substrate 1.

Authors:  Xiaoqin Xiang; Mingsheng Yuan; Ying Song; Neil Ruderman; Rong Wen; Zhijun Luo
Journal:  Mol Endocrinol       Date:  2002-03

10.  The 47kDa Akt substrate associates with phosphodiesterase 3B and regulates its level in adipocytes.

Authors:  Jose A Chavez; Scott Gridley; Hiroyuki Sano; William S Lane; Gustav E Lienhard
Journal:  Biochem Biophys Res Commun       Date:  2006-02-24       Impact factor: 3.575

View more
  26 in total

1.  The biological activity of structurally defined inositol glycans.

Authors:  Meenakshi Goel; Viatcheslav N Azev; Marc d'Alarcao
Journal:  Future Med Chem       Date:  2009-04       Impact factor: 3.808

Review 2.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 3.  From PDE3B to the regulation of energy homeostasis.

Authors:  Eva Degerman; Faiyaz Ahmad; Youn Wook Chung; Emilia Guirguis; Bilal Omar; Lena Stenson; Vincent Manganiello
Journal:  Curr Opin Pharmacol       Date:  2011-10-14       Impact factor: 5.547

4.  Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury.

Authors:  Youn Wook Chung; Claudia Lagranha; Yong Chen; Junhui Sun; Guang Tong; Steven C Hockman; Faiyaz Ahmad; Shervin G Esfahani; Dahae H Bae; Nazari Polidovitch; Jian Wu; Dong Keun Rhee; Beom Seob Lee; Marjan Gucek; Mathew P Daniels; Christine A Brantner; Peter H Backx; Elizabeth Murphy; Vincent C Manganiello
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-15       Impact factor: 11.205

5.  Selective insulin resistance in adipocytes.

Authors:  Shi-Xiong Tan; Kelsey H Fisher-Wellman; Daniel J Fazakerley; Yvonne Ng; Himani Pant; Jia Li; Christopher C Meoli; Adelle C F Coster; Jacqueline Stöckli; David E James
Journal:  J Biol Chem       Date:  2015-02-26       Impact factor: 5.157

6.  The Role of PDE3B Phosphorylation in the Inhibition of Lipolysis by Insulin.

Authors:  Lisa M DiPilato; Faiyaz Ahmad; Matthew Harms; Patrick Seale; Vincent Manganiello; Morris J Birnbaum
Journal:  Mol Cell Biol       Date:  2015-06-01       Impact factor: 4.272

7.  The role of mouse Akt2 in insulin-dependent suppression of adipocyte lipolysis in vivo.

Authors:  Shlomit Koren; Lisa M DiPilato; Matthew J Emmett; Abigail L Shearin; Qingwei Chu; Bob Monks; Morris J Birnbaum
Journal:  Diabetologia       Date:  2015-03-05       Impact factor: 10.122

8.  Molecular mechanism of antidiabetic zinc-allixin complexes: regulations of glucose utilization and lipid metabolism.

Authors:  Akihiro Nakayama; Makoto Hiromura; Yusuke Adachi; Hiromu Sakurai
Journal:  J Biol Inorg Chem       Date:  2008-02-21       Impact factor: 3.358

Review 9.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

Review 10.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.